Clinical trials recruiting for Mesothelioma
27
Recruiting trials
35
US states with sites
8
Countries
7%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Florida | 10 |
| Texas | 10 |
| New York | 8 |
| Ohio | 8 |
| California | 7 |
| Maryland | 7 |
| Minnesota | 7 |
| Arizona | 6 |
| Illinois | 6 |
| Massachusetts | 6 |
| Pennsylvania | 6 |
| Missouri | 5 |
Top cities
Houston, Texas 8New York, New York 7Chicago, Illinois 5Columbus, Ohio 5Fairfax, Virginia 5Nashville, Tennessee 5Rochester, Minnesota 5Seattle, Washington 5Bethesda, Maryland 4Boston, Massachusetts 4
Self-screener
Recruiting trials
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- A 2-part Phase 1/2 Open-label Trial on ODM-212
- A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
- A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
- A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- A Study of VET3-TGI in Patients With Solid Tumors
- A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- Agnostic Therapy in Rare Solid Tumors
- An International Study on Pediatric Patients With Rare Tumors.
- Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
- Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
- Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
- First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
- Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- GPC3/Mesothelin-CAR-γδT Cells Against Cancers
- Integrated Cancer Repository for Cancer Research
- Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Olaparib in Patients With HRD Malignant Mesothelioma
- Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
- Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Prospective Data Collection Initiative on Thoracic Malignancies
- Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Stereotactic Magnetic Resonance Guided Radiation Therapy
- Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
- VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Related conditions
Trials recruiting for Mesothelioma often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Pancreatic cancer 870Non-small cell lung cancer 507Colorectal cancer 1359Breast cancer 2239Ovarian cancer 118Solid Tumor, Adult 38Pancreas Cancer 86Mesothelioma, Malignant 9Melanoma 487
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Mesothelioma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.